Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Mar 23, 2009

Merck Gains Rights Xencor's Antibody Platform for $3M

  • Merck & Co. inked a deal to license Xencor's antibody half-life prolongation technology for $3 million up front as well as an undisclosed fee upon choosing an Xtend variant. Additional payments are stipulated for clinical development milestones and royalties on product sales.

    Xencor's antibody platform enhances the serum half-life of immunoglobin molecules in different therapeutic indications by using antibody Fc variants. Other Xencor drug candidates for lymphoma indications such as anti-CD30 candidate XmAb2513 have completed Phase I clinical testing.

    Xencor has entered into agreements concerning antibody Fc domains with other companies including Pfizer, Genentech, CSL, Boehringer Ingelheim, MedImmune, and Human Genome Sciences.



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »